Department of Biosciences, University of Oslo , N-0371 Oslo, Norway.
Tumor Immunology lab, Department of Pathology, Rikshospitalet, Oslo University Hospital and University of Oslo , N-0424 Oslo, Norway.
Mol Pharm. 2017 Nov 6;14(11):4098-4112. doi: 10.1021/acs.molpharmaceut.7b00795. Epub 2017 Oct 19.
The attenuated live vaccine strain bacille Calmette-Guérin (BCG) is currently the only available vaccine against tuberculosis (TB), but is largely ineffective against adult pulmonary TB, the most common disease form. This is in part due to BCG's ability to interfere with the host innate immune response, a feature that might be targeted to enhance the potency of this vaccine. Here, we investigated the ability of chitosan-based nanoparticles (pIC-NPs) containing polyinosinic-polycytidylic acid (poly(I:C)), an inducer of innate immunity via Toll-like receptor 3 (TLR3), to enhance the immunogenicity of BCG in mouse bone marrow derived macrophages (BMDM) in vitro. Incorporation of poly(I:C) into NPs protected it against degradation by ribonucleases and increased its uptake by mouse BMDM. Whereas soluble poly(I:C) was ineffective, pIC-NPs strongly enhanced the proinflammatory immune response of BCG-infected macrophages in a synergistic fashion, as evident by increased production of cytokines and induction of nitric oxide synthesis. Using macrophages from mice deficient in key signaling molecules involved in the pathogen recognition response, we identified combined activation of MyD88- and TRIF-dependent TLR signaling pathways to be essential for the synergistic effect between BCG and NP. Moreover, synergy was strongly dependent on the order of the two stimuli, with TLR activation by BCG functioning as the priming event for the subsequent pIC-NP stimulus, which acted through an auto-/paracrine type I interferon (IFN) feedback loop. Our results provide a foundation for a promising new approach to enhance BCG-vaccine immunogenicity by costimulation with NPs. They also contribute to a molecular understanding of the observed synergistic interaction between the pIC-NPs and BCG vaccine.
减毒活疫苗卡介苗(BCG)目前是唯一可用的结核病(TB)疫苗,但对成人肺结核(最常见的疾病形式)的效果大多不佳。这在一定程度上是由于 BCG 能够干扰宿主先天免疫反应,而这一特性可能是针对增强这种疫苗效力的目标。在这里,我们研究了含有聚肌苷酸-聚胞苷酸(poly(I:C))的壳聚糖纳米颗粒(pIC-NPs)通过 Toll 样受体 3(TLR3)诱导先天免疫的能力,以增强卡介苗在体外小鼠骨髓来源巨噬细胞(BMDM)中的免疫原性。将 poly(I:C) 掺入 NPs 中可防止其被核糖核酸酶降解,并增加其被小鼠 BMDM 的摄取。虽然可溶性 poly(I:C)无效,但 pIC-NPs 以协同方式强烈增强了 BCG 感染的巨噬细胞的促炎免疫反应,这表现为细胞因子的产生增加和一氧化氮合成的诱导。使用参与病原体识别反应的关键信号分子缺失的巨噬细胞,我们确定了 MyD88 和 TRIF 依赖性 TLR 信号通路的联合激活对于 BCG 和 NP 之间的协同作用是必需的。此外,协同作用强烈依赖于两种刺激物的顺序,BCG 对 TLR 的激活作为随后 pIC-NP 刺激物的启动事件,该刺激物通过自分泌/旁分泌 I 型干扰素(IFN)反馈环起作用。我们的结果为通过与 NPs 共刺激来增强 BCG 疫苗免疫原性提供了一种有前途的新方法的基础。它们还为观察到的 pIC-NPs 和 BCG 疫苗之间的协同相互作用提供了分子理解。
Vaccines (Basel). 2024-11-27
Eur J Pharm Biopharm. 2024-4
Crit Rev Microbiol. 2024-3
Vaccines (Basel). 2022-3-10
Vaccines (Basel). 2022-1-14
Front Immunol. 2021